| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000019999 |
| Receipt No. | R000023087 |
| Official scientific title of the study | Safety and efficay assessment of adenosine A2A receptor ligand [C-11]Preladenant in healthy volunteers. |
| Date of disclosure of the study information | 2015/12/01 |
| Last modified on | 2017/11/20 (Ver. 7) |
| Basic information | ||
| Official scientific title of the study | Safety and efficay assessment of adenosine A2A receptor ligand [C-11]Preladenant in healthy volunteers. | |
| Title of the study (Brief title) | First-in-human study of [C-11] Preladenant. | |
| Region |
|
|
| Condition | |||||
| Condition | Healthy volunteer | ||||
| Classification by specialty |
|
||||
| Classification by malignancy | Others | ||||
| Genomic information | NO | ||||
| Objectives | |
| Narrative objectives1 | First-in-human study of [C-11]Preladenant. Assessment of safety, efficacy and dosimetry in healthy volunteers. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | Phase I |
| Assessment | |
| Primary outcomes | Safety: Adverse Drug Reaction (symptoms, blood pressure, respiratory rate, heart rate, general blood tests)
Efficacy: Quality and analyzability of PET/CT image. Dosimetry Date of evaluation: on the day and one week after the PET scan |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | The dosage in the vain of [C-11]CB184 for PET/CT imaging.
Term of injection: On the day of PET/CT imaging. Dosage:185-740 MBq (Maximum substance at 37 microgram) Number of injection: once |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | 1. The subject who has intention to participate in this study, and signed informed consent.
2. Male subject of >=20 and =<60 years old. 3. The subject who judged by clinical investigator by means of physical examination and laboratory tests to be eligible as a participant in this study. |
|||
| Key exclusion criteria | 1. The subject who has dysfunction in the liver / kidney.
2. The subject who has abnormal findings in the central nervous system. 3. The subject having cardiac failure. 4. The subject with a history of a drug or food allergy. 5. The subject who juddged by the clinical investigator to be inappropriate as a participant in this study. |
|||
| Target sample size | 15 | |||
| Research contact person | |
| Name of lead principal investigator | Kenji Ishii |
| Organization | Tokoyo Metropolitan Institute of Gerontology |
| Division name | Research Team for Neuroimaging |
| Address | 35-2 Sakae-cho, Itabashi-ku, Tokyo |
| TEL | 03-3964-3241 |
| ishii@pet.tmig.or.jp | |
| Public contact | |
| Name of contact person | Kenji Ishii |
| Organization | Tokoyo Metropolitan Institute of Gerontology |
| Division name | Research Team for Neuroimaging |
| Address | 35-2 Sakae-cho, Itabashi-ku, Tokyo |
| TEL | 03-3964-3241 |
| Homepage URL | |
| ishii@pet.tmig.or.jp | |
| Sponsor | |
| Institute | Tokoyo Metropolitan Institute of Gerontology |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Tokyo Metropolitan Institute of Gerontology |
| Organization | |
| Division | |
| Category of Funding Organization | Local Government |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 地方独立行政法人東京都健康長寿医療センター研究所 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023087 |